PCSK9 monokloonsed antikehad düslipideemia raviks: evolokumab ja alirokumab

Alar Irs

Abstract


Euroopa Ravimiameti (European Medicines Agency, EMA) inimravimite komitee (Committee for Human Medicinal Products, CHMP) soovitas anda müügiloa kahele uuele sama toimemehhanismiga düslipideemiaravimile: evolokumabile (Repatha, Amgen) ja alirokumabile (Praluent, sanofi aventis).

 

Eesti Arst 2015; 94(9):567–570



Full Text:

PDF


DOI: https://doi.org/10.15157/ea.v0i0.12350

Refbacks

  • There are currently no refbacks.